BeyondSpring (NASDAQ:BYSI) Stock Passes Below 50-Day Moving Average – Should You Sell?

BeyondSpring Inc. (NASDAQ:BYSI) shares crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.53 and traded as low as $1.46. BeyondSpring shares last traded at $1.49, with a volume of 12,878 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of BeyondSpring in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

BeyondSpring Price Performance

The company has a fifty day simple moving average of $1.53 and a two-hundred day simple moving average of $1.76. The company has a market capitalization of $60.09 million, a P/E ratio of -9.93 and a beta of 0.56.

Institutional Investors Weigh In On BeyondSpring

An institutional investor recently bought a new position in BeyondSpring stock. State Street Corp purchased a new stake in shares of BeyondSpring Inc. (NASDAQ:BYSI) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 231,120 shares of the company’s stock, valued at approximately $377,000. State Street Corp owned about 0.57% of BeyondSpring as of its most recent SEC filing. 40.29% of the stock is owned by hedge funds and other institutional investors.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.